Effect modification of the association between vancomycin trough concentration and acute kidney injury: A retrospective cohort study
Vancomycin exposure is associated with acute kidney injury (AKI), but the extent to which concomitant clinical factors modify this association remains uncertain. This study evaluated factors associated with vancomycin-related AKI and examined potential effect modification of the association between vancomycin trough concentration and AKI. This single-center retrospective cohort study used electronic health records of adults treated with vancomycin from January 2019 to June 2023. Factors associated with AKI were assessed using logistic regression, and interaction terms were used to evaluate whether the trough-AKI association differed according to selected comorbidities and concomitant medications. A systematic review and meta-analysis were also performed to place the cohort findings in the context of existing evidence. Among 1612 patients, 375 (23.2%) developed AKI. Higher vancomycin trough concentration, concomitant loop diuretic use, and concomitant piperacillin/tazobactam (PIP/TAZ) use were independently associated with AKI. Statistically significant interactions with trough concentration were observed for PIP/TAZ, chronic kidney disease, hypertension, and angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker use (interaction P = .036, .023, .003, and .006, respectively). Compared with patients not receiving PIP/TAZ and with trough levels < 17 mg/L, the odds of AKI were higher among patients receiving PIP/TAZ with trough levels < 17 mg/L (odds ratio [OR]: 1.62, 95% CI: 1.42-1.85) and were highest among those receiving PIP/TAZ with trough levels ≥17 mg/L (OR: 2.03, 95% CI: 1.36-2.98). Among patients not receiving PIP/TAZ, trough levels ≥17 mg/L were associated with higher AKI odds (OR: 1.43, 95% CI: 1.26-1.63). Concomitant PIP/TAZ identified a population with increased AKI risk across trough strata, whereas the incremental association of a higher trough level was less apparent among PIP/TAZ users. These observational findings support individualized assessment of vancomycin exposure together with concurrent AKI risk factors and should not be interpreted as establishing a new therapeutic trough target.
Authors
- Chun-Hao Yin (ORCID: https://orcid.org/0000-0002-2534-9589)
- Yi‐Chia Su (ORCID: https://orcid.org/0000-0002-9544-1153)
- Ying‐Chun Li (ORCID: https://orcid.org/0000-0001-8516-970X)
- Ching-Shiang Yang
- Yao-Shen Chen
- Cheng-Len Sy
- Jin-Shuen Chen
- Kuan-Sheng Wu
- Yu-Ling Tseng
Institutions
- National Tainan Institute of Nursing (TW)
- National Sun Yat-sen University (TW)
- National Yang Ming Chiao Tung University (TW)
- Kaohsiung Medical University (TW)
- Tajen University (TW)
- Kaohsiung Veterans General Hospital (TW)
- Chia Nan University of Pharmacy and Science (TW)
- National Cheng Kung University (TW)
Publication Details
- Journal
- Medicine
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1097/md.0000000000051407
- Primary Topic
- Acute Kidney Injury Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00